Trupanion, Inc. (NASDAQ:TRUP – Get Free Report) CEO Margaret Tooth sold 491 shares of the business’s stock in a transaction that occurred on Monday, May 25th. The shares were sold at an average price of $21.86, for a total transaction of $10,733.26. Following the transaction, the chief executive officer directly owned 176,379 shares in the company, valued at $3,855,644.94. The trade was a 0.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Trupanion Stock Performance
TRUP stock opened at $22.15 on Friday. The firm has a 50 day moving average of $25.00 and a two-hundred day moving average of $30.40. The company has a quick ratio of 1.73, a current ratio of 1.73 and a debt-to-equity ratio of 0.25. Trupanion, Inc. has a 12 month low of $21.16 and a 12 month high of $57.88. The company has a market capitalization of $966.18 million, a price-to-earnings ratio of 37.54 and a beta of 1.49.
Trupanion (NASDAQ:TRUP – Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The financial services provider reported $0.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.07 by $0.04. Trupanion had a net margin of 1.74% and a return on equity of 6.87%. The company had revenue of $384.05 million during the quarter, compared to analysts’ expectations of $379.77 million. During the same quarter in the prior year, the company posted ($0.03) EPS. The business’s revenue was up 12.3% on a year-over-year basis. As a group, equities analysts anticipate that Trupanion, Inc. will post 0.53 EPS for the current fiscal year.
Institutional Trading of Trupanion
Wall Street Analyst Weigh In
Several research analysts have recently issued reports on the stock. Piper Sandler reduced their target price on shares of Trupanion from $60.00 to $45.00 and set an “overweight” rating on the stock in a research note on Friday, February 13th. Stifel Nicolaus lowered their price objective on shares of Trupanion from $35.00 to $31.00 and set a “hold” rating on the stock in a report on Tuesday, March 31st. Zacks Research downgraded shares of Trupanion from a “strong-buy” rating to a “hold” rating in a report on Friday, February 13th. Weiss Ratings cut shares of Trupanion from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, March 4th. Finally, Cantor Fitzgerald decreased their target price on shares of Trupanion from $42.00 to $34.00 and set a “neutral” rating for the company in a research note on Thursday, April 9th. Two investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Trupanion currently has an average rating of “Hold” and a consensus price target of $42.25.
Read Our Latest Stock Report on Trupanion
About Trupanion
Trupanion, Inc is a pet medical insurance company that provides comprehensive insurance coverage for cats and dogs. The company’s core offering is a single, customizable medical policy designed to cover veterinary diagnostic tests, surgeries, hospital stays and congenital or hereditary conditions. Trupanion seeks to streamline the claims process by offering direct payment options to participating veterinarians, reducing the need for upfront payments by pet owners.
Founded in 1999 by Darryl Rawlings and headquartered in Seattle, Washington, Trupanion began operations in the early 2000s and has grown its presence through both digital channels and partnerships with veterinary hospitals.
See Also
- Five stocks we like better than Trupanion
- 3 Stocks Rallying on Micron’s Price Boost: Substance or Hype?
- Snowflake and the Snowballing Impact of its AI Flywheel
- AI’s Biggest Bottleneck Could Make These 2 Stocks Soar
- These 3 Beaten-Down Stocks Just Saw $25 Million in Insider Buying
Receive News & Ratings for Trupanion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trupanion and related companies with MarketBeat.com's FREE daily email newsletter.
